Companies › Theravia
1 active drug program in 14 registered trials: 7 Phase 2, 4 Phase 1, 2 Phase 4, 1 Phase 3; Hematology, Immunology, Oncology; next expected readout Feb 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Hydroxyurea Ribonucleoside-diphosphate reductase RR1 inhibitor | RRM1, RRM2B, RRM2 | Phase 2 | Sickle Cell Disease; Sickle Cell Anemia (HbSS); Sickle Cell Anemia in Children; Primary Immunodeficiency (PID) … | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT01962415 | Hydroxyurea | Phase 2 | Primary Immunodeficiency (PID) | Immunology | Nov 2026 |
| NCT07177300 | Hydroxyurea | Phase 4 | Sickle Cell Anemia (HbSS) | Hematology | Dec 2026 |
| NCT00920972 | Hydroxyurea | Phase 1 | Metabolic Disorders | Oncology | Dec 2026 |
| NCT03948867 | Hydroxyurea | Phase 2 | Sickle Cell Anemia in Children | Hematology | Dec 2026 |
| NCT05285917 | Hydroxyurea | Phase 3 | Sickle Cell Anemia in Children | Hematology | Sep 2027 |
| NCT06171217 | Hydroxyurea | Phase 2 | Sickle Cell Disease | Hematology | Oct 2027 |
| NCT06578507 | Hydroxyurea | Phase 2 | Sickle Cell Disease | Hematology | Feb 2028 |
| NCT06761560 | Hydroxyurea | Phase 2 | Sickle Cell Disease (SCD) | Hematology | Nov 2028 |
| NCT04362293 | Hydroxyurea | Phase 2 | Sickle Cell Disease | Hematology | Aug 2029 |
| NCT04362293 | Hydroxyurea | Phase 2 | Sickle Cell Disease | Hematology | Aug 2029 |
| NCT06199557 | Hydroxyurea | Phase 1 | Acute Myeloid Leukemia, Adult | Oncology | Sep 2029 |
| NCT06526117 | Hydroxyurea | Phase 4 | Sickle Cell Disease | Hematology | Dec 2029 |
| NCT07708714 | Hydroxyurea | Phase 1 | Sickle Cell Disease | Hematology | Nov 2030 |
| NCT01966731 | Hydroxyurea | Phase 1 | Sickle Cell Disease | Hematology | Aug 2033 |
InnoPharmax Electra Therapeutics Syntrix Biosystems Tavotek Biotherapeutics Xizang Haisco Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.